A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

← catalyst calendar

NCT07142811 · readout ≤ 103 d

Sponsored by Vir Biotechnology, Inc. (industry) · VIR — their whole pipeline →.

Phase

Phase 2

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

100estimated

Sites

Countries

Belgium, Bulgaria, France +8

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-08-05

actual

When the study began enrolling

Primary completion

Nov 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jul 2030

estimated

The whole study's end, after follow-up

First posted

2025-08-27

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-01-16

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Viral Hepatitis

Interventions

Drug: Tobevibart — also filed as VIR-3434
Drug: Elebsiran — also filed as VIR-2218
Drug: Bulevirtide — also filed as Hepcludex

Primary outcomes

what the primary-completion date above is the date OF

HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 48

measured Week 48

HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) 24 weeks after end of treatment

measured 24 Weeks after End of Treatment

Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through Week 48

measured Week 48

Publications

PMID 41586499 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · VIR's whole pipeline · Catalyst calendar · Every registered study · What changed